연구동향 분석

ORIGINAL ARTICLE : Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials

( Gwan Gyu Song ) ( Sang Cheol Bae ) ( Young Ho Lee ) 2014년

논문상세정보
인용/피인용
' ORIGINAL ARTICLE : Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • arthritis
  • efficacy
  • rheumatoid
  • safety
  • tofacitinib
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
801 0

0.0%

' ORIGINAL ARTICLE : Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials' 의 참고문헌

  • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
    van Vollenhoven RF N Engl J Med 367 : 508 ~ 519 [2012]
  • Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
    Tanaka Y Arthritis Care Res (Hoboken) 63 : 1150 ~ 1158 - [2011]
  • The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550versus placebo
    Kremer JM Arthritis Rheum 60 : 1895 ~ 1905 - [2009]
  • The pathogenesis of rheumatoid arthritis
    McInnes IB N Engl J Med 365 : 2205 ~ 2219 - [2011]
  • Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials
    Lee YH Scand J Rheumatol 39 : 271 ~ 278 - [2010]
  • Structural and thermodynamic characterization of the TYK2 and JAK3kinase domains in complex with CP-690550 and CMP-6
    Chrencik JE J Mol Biol 400 : 413 ~ 433 - [2010]
  • Rheumatoid arthritis: pathophysiology and implications for therapy
    Harris ED Jr N Engl J Med 322 : 1277 ~ 1289 [1990]
  • Quantifying heterogeneity in a meta-analysis
    Higgins JP Stat Med 21 : 1539 ~ 1558 - [2002]
  • Prevention of organ allograft rejection by a specific Janus kinase 3inhibitor
    Changelian PS Science 302 : 875 ~ 878 - [2003]
  • Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
    Fleischmann R N Engl J Med 367 : 495 ~ 507 - [2012]
  • Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Fleischmann R Arthritis Rheum 64 : 617 ~ 629 - [2012]
  • Meta-analysis: principles and procedures
    Egger M BMJ 315 : 1533 ~ 1537 - [1997]
  • Meta-analysis in clinical trials
    DerSimonian R Control Clin Trials 7 : 177 ~ 188 - [1986]
  • Janus kinases in immune cell signaling
    Ghoreschi K Immunol Rev 228 : 273 ~ 287 - [2009]
  • Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
    Coombs JH Ann Rheum Dis 69 : 413 ~ 416 - [2010]
  • Genome scan meta-analysis of rheumatoid arthritis
    Choi SJ Rheumatology (Oxford) 45 : 166 ~ 170 - [2006]
  • FDA approves tofacitinib for rheumatoid arthritis
    Traynor K Am J Health Syst Pharm 69 : 2120 ~ [2012]
  • Bias in metaanalysis detected by a simple, graphical test
    Egger M BMJ 315 : 629 ~ 634 - [1997]
  • Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis
    Lee YH Rheumatol Int 27 : 2006 ~ 2027 [2006]
  • Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
    Meyer DM J Inflamm (Lond) 7 : 41 ~ - [2010]
  • A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    Kremer JM Arthritis Rheum 64 : 970 ~ 981 - [2012]